UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Not sure what you can access? Learn more about account types.

Diverticulitis: When not to be worried?

Johannes Kurt Schultz 1

1 Univertsity of Oslo, Oslo, Norway

Event

UEG Week Berlin 2025

Topics

Colorectal Hepatobiliary Pancreas

Session

Predicting disease severity

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Variceal bleeding from Ligation to Sengstaken

Thomas Rösch 1

1 Clinic for Interdisciplinary Endoscopy, Hamburg, Germany

Event

UEG Week Berlin 2025

Topics

Nurses

Session

Endoscopic techniques: Emergency and difficult situations

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Can we harmonise methods of microbiological surveillance

Heike Martiny, Prof. Dr. 1

1 Charité - Universitätsmedizin Campus Benjamin Franklin, CC 5, Berlin, Germany

Event

UEG Week Berlin 2025

Topics

Nurses

Session

Hygiene: Update 2025

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Portal vein thrombosis: Aetiologies and differential management

Verena Keitel-Anselmino 1

1 University Hospital Magdeburg, Magdeburg, Germany

Event

UEG Week Berlin 2025

Topics

Hepatobiliary

Session

What's new in complications in chronic liver disease in 2025?

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

LINERIXIBAT SIGNIFICANTLY IMPROVES CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS: RESULTS OF THE PIVOTAL PHASE 3 GLISTEN TRIAL

Not sure what you can access? Learn more about account types.

Introduction

Cholestatic pruritus is common, debilitating and undertreated in patients with primary biliary cholangitis (PBC). Here, we describe the results of GLISTEN (NCT04950127), a Phase 3 study investigating the efficacy and safety of the ileal bile acid transporter inhibitor linerixibat for pruritus in PBC.

Aims & Methods

In this double-blind, randomised, placebo-controlled study, patients with PBC and moderate-to-severe pruritus received oral linerixibat 40 mg or placebo twice daily. Pruritus severity and pruritus-related sleep interference were assessed using a 0–10 numerical rating scale. The primary endpoint was change from baseline in worst itch over 24 weeks. Secondary endpoints included: at Week 2, change in worst itch; over 24 weeks, change in sleep interference; at Week 24, proportion of responders (≥ 2-, ≥ 3-, ≥ 4-point reduction in worst itch) and analysis of responses to 2 patient global impression items (itch severity and change). Safety endpoints included adverse event (AE) reporting.

Results

238 patients were randomised; 95% were female, itch severity was mean (standard deviation [SD]) 7.34 (1.54), 52% had alkaline phosphatase < 1.67 times upper limit of normal, and 47% were receiving stable therapy for pruritus. Pruritus improvement over 24 weeks was significantly greater with linerixibat than placebo: least-squares (LS) mean change -2.86 versus -2.15, adjusted mean difference -0.72; p = 0.001. At Week 24, the observed mean (SD) difference from baseline in pruritus was -3.66 (2.50) with linerixibat and -2.82 (2.32) with placebo. The effect of linerixibat was rapid and superior to placebo at Week 2: LS mean change -1.78 versus -1.07, adjusted mean difference -0.71; p < 0.001. Linerixibat also significantly improved pruritus-related sleep interference over 24 weeks versus placebo: LS mean change ‑2.77 versus -2.24, adjusted mean difference -0.53; p = 0.024. At Week 24, more patients on linerixibat than placebo achieved a ≥ 2-point (68% vs 64%), ≥ 3-point (56% vs 43%) or ≥ 4-point (41% vs 29%) reduction in pruritus and a higher proportion of linerixibat than placebo-treated patients reported their pruritus was very much improved (55% vs 37%) or absent (21% vs 9%). AEs reported more frequently with linerixibat than placebo were predominantly gastrointestinal (GI), including diarrhoea (61% vs 18% of patients) and abdominal pain (18% vs 3% of patients); 4% of patients in the linerixibat group discontinued treatment due to diarrhoea.

Conclusion

In patients with PBC and moderate-to-severe pruritus, linerixibat rapidly and significantly improved pruritus and pruritus-related sleep interference versus placebo. While GI AEs were more common with linerixibat than placebo, they rarely led to treatment discontinuation.

Disclosure

Funded by GSK. Various authors declare conflicts of interest as consultants, employee, recipients of grants and stockholders. These will be reported in full during the presentation.

LINERIXIBAT SIGNIFICANTLY IMPROVES CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS: RESULTS OF THE PIVOTAL PHASE 3 GLISTEN TRIAL

Gideon M. Hirschfield 1, Christopher L. Bowlus 2, David Jones 3, Andreas E. Kremer 4, Marlyn J. Mayo 5, Atsushi Tanaka 6, Pietro Andreone 7, Jidong Jia 8, Qinglong Jin 9, Ricardo Macias-Rodriguez 10, Alexander R. Cobitz 11, Brooke M. Currie 11, Ciara Gorey 12, Ivana Lazic 12, Danielle J. Podmore 12, Andrea Ribiero 13, Jennifer B. Shannon 14, Brandon Swift 14, Megan M. McLaughlin 11, Cynthia Levy 15

1 Toronto General Hospital, Toronto, Canada

2 University of California Davis School of Medicine, Sacramento, United States

3 Newcastle University, Newcastle Upon Tyne, United Kingdom

4 University Hospital Zurich, Zurich, Switzerland

5 University of Texas Southwestern Medical School, Dallas, United States

6 Teikyo University School of Medicine, Tokyo, Japan

7 Azienda Ospedaliero-Universitaria di Modena and Università di Modena e Reggio Emilia, Modena, Italy

8 Capital Medical University, Beijing, China

9 The First Hospital of Jilin University, Changchun, China

10 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

11 GSK, Collegeville, United States

12 GSK, London, United Kingdom

13 GSK, Madrid, Spain

14 GSK, Durham, United States

15 University of Miami, Miami, United States

Event

UEG Week Berlin 2025

Topics

Hepatobiliary Immunology Mechanisms & Personalised Medicine

Submission format

Abstract

Session

Advances in management of immune-mediated biliary disease

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

CONCOMITANT ATOPY INFLUENCES RESPONSE TO PROTON-PUMP INHIBITORS IN EOSINOPHILIC ESOPHAGITIS: AN ANALYSIS OF THE EOE CONNECT REGISTRY

Not sure what you can access? Learn more about account types.

Introduction

Eosinophilic esophagitis (EoE) is type-2 chronic inflammatory disorder usually accompanied by other atopic conditions including rhinitis, conjunctivitis, bronchial asthma, dermatitis, hives or chronic rhinosinusitis with nasal polyps. The influence of these atopies in the response to the EoE therapy has been barely investigated, with opposite results in small cohorts (1,2).

Aims & Methods

We aim to describe atopic concomitances in European EoE patients and to evaluate its influence on effectiveness of first-line therapy, consisting in proton-pump inhibitors (PPIs), swallowed topical corticosteroids (STCs) and food-elimination diets (FEDs).
A cross-sectional analysis of the multicenter EoE CONNECT registry (3) was performed. Demographic and clinical data from patients recruited at 42 hospitals in 4 European countries were extracted on March 25^th, 2025. Concomitant atopies were classified as seasonal or persistent. Clinico-histological response (CHR) was defined as the simultaneous presence of symptomatic remission and a peak eosinophil count <15 eosinophils per high power field after therapy.

Results

Overall, 3,900 patients (75.6% males, mean age 33.3 ±15.1 years) were analyzed (Table). CHR rate after first-line monotherapy with PPIs, STCs or FEDs was 50.4% (n=2,685). PPIs was the only treatment affected by concomitant atopy: presence of asthma and hives significantly reduced CHR rates to PPIs (42.7% vs 49.7%, p=0.005, and 39.3% vs 48%, p=0.044, respectively), and CHR also tended to be lower in presence of conjunctivitis (43.6% vs 48.4, p=0.067) and dermatitis (43.2% vs 48.3%, p=0.081). Seasonal or persistent presentation of atopy did not influence response to treatment. Taking into account age at diagnosis, the effect of concomitant atopy in reducing CHR to PPIs was exclusively observed in adults (≥18 years old) for asthma (43.8% vs 51.3%, p=0.007) and dermatitis (42.6% vs 50.3%, p=0.026), and in children (<18 years old) for hives (17.4% vs 39.9%, p=0.032).
We next analyzed whether the number of concomitant atopies influenced CHR to first-line therapy. While no differences were found among patients who presented only one atopic condition, the presence of 2 or more atopies reduced PPI effectiveness in adults (45.0% vs 50.7%, p=0.032) and to FEDs in children (23.5% vs 59.3%, p=0.020). A reduction in CHR rate after PPI therapy was even greater in adults with 3 or more atopies concomitant to EoE (39.0% vs 50.4%, p=0.001). Effectiveness of first-line STCs were not affected in any of these comparisons.

Age at diagnosis (n=3,705)	<18 years: 19.4%; ≥18 years: 80.6%
Rhinitis (n=3,558)	49.4 %; Seasonal 77.3 %; Persistent 22.7%
Conjunctivitis (n=3,499)	23.8%; Seasonal 88.5%; Persistent 11.5%
Asthma (n=3,526)	28.6%; Seasonal 63.8%; Persistent 36.2%
Dermatitis (n=3,507)	18.7%; Seasonal 43.4%; Persistent 56.6%
Hives (n=3,403)	7.1%; Seasonal 50.7 %; Persistent 49.3%
Chronic rhinosinusitis with nasal polyps (n=3,461)	2.1%; Persistent: 100%
Number of allergies (n=3,353)	At least 1 allergy: 64.7%; ≥2 allergies: 39.1%; ≥3 allergies: 17.4%
Response to 1st treatment option in monotherapy evaluated (n=3,266)	PPI: 82.6%; STC: 11.9%; FED: 5.5%

Conclusion

The coexistence of asthma, dermatitis and hives determined lower response to PPI therapy for EoE. Association of 2 or more atopic condition further decreased effectiveness of PPIs in adults and of FEDs in children.

References

1. Ancellin M, Ricolfi-Waligova L, Clerc-Urmès I, et al. Management of eosinophilic esophagitis in children according to atopic status: a retrospective cohort in northeast of France. Arch Pediatr. 2020;27(3):122-127.
2. Reed WD, Ocampo AA, Xue Z, et al. Eosinophilic esophagitis patients with multiple atopic conditions: clinical characteristics and treatment response to topical steroids. Ann Allergy Asthma Immunol. 2023;131(1): 109-115.e2.
3. Lucendo AJ, Santander C, Savarino E, et al. EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe. Therap Adv Gastroenterol. 2022;15:17562848221074204.

CONCOMITANT ATOPY INFLUENCES RESPONSE TO PROTON-PUMP INHIBITORS IN EOSINOPHILIC ESOPHAGITIS: AN ANALYSIS OF THE EOE CONNECT REGISTRY

Leticia Rodríguez-Alcolado 1, Emilio Jose Laserna-Mendieta 2, Victoria Úbeda Vargas 3, Sergio Casabona-Francés 4, Edurne Amorena Muro 5, Leonardo Blas 6, Edoardo Vincenzo Savarino 7, Isabel Pérez-Martínez 8, Jesús Barrio Andrés 9, Antonio Guardiola Arevalo 10, Danila Guagnozzi 11, Marina Coletta 12, Laura Martín Asenjo 13, Luisa de la Peña Negro 14, Gaia Pellegatta 15, Alejandro García-Díaz 16, Elena Betoré 17, Anne Lund Krarup 18, Susana de la Riva 19, Silvia Carrión Bolorino 20, María Pipa 21, Sonia Fernandez-Fernandez 22, Carlos Teruel Sanchez - Vegazo 23, Juan Enrique Naves 24, BLANCA BELLOC 25, Salvatore Oliva 26, Mónica Llorente-Barrio 27, Carlo Maria Rossi 28, Juan Armando Rodríguez Oballe 29, Maria Luisa Masiques-Mas 30, Raúl Honrubia-López 31, Raffaella Dainese Plichon 32, Alexis González Almeida 33, Luis Bujanda Fernández de Piérola 34, Juan Khaled Bisso Zein 35, Alba Juan-Juan 36, Sara Feo Ortega 3, Verónica Martín Domínguez 4, Jennifer Fernández-Pacheco 4, Oscar Nantes Castillejo 5, Julia Nicolay Maneru 5, Marta Álvarez-García 6, Matteo Ghisa 7, Carmen Díaz-Donado 37, Paula Gil Simón 9, Alicia Granja 10, Ronald Llerena Castro 11, Roberto Penagini 12, Cecilio Santander 4, Alfredo J. Lucendo 2

1 Hospital General de Tomelloso, Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Tomelloso, Spain|||University of Alcalá, Alcalá de Henares, Spain

2 Hospital General de Tomelloso, Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Tomelloso, Spain|||Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain

3 Hospital General de Tomelloso, Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Tomelloso, Spain

4 Hospital Universitario de La Princesa, Madrid, Spain|||Instituto de Investigación Sanitaria La Princesa, Madrid, Spain

5 Hospital Universitario de Navarra. Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain

6 Fundacion Jiménez Díaz, Madrid, Spain

7 Azienda Ospedaliera Università di Padova, Padua, Italy

8 Hospital Universitario Central de Asturias, Oviedo, Spain|||Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain

9 Hospital Universitario Rio Hortega, Valladolid, Spain

10 Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain

11 Hospital Vall d'Hebrón, Barcelona, Spain

12 Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, Milan, Italy

13 Hospital Universitario de Álava, Vitoria, Spain

14 Hospital de Viladecans, Viladecans, Spain

15 Humanitas Research Hospital, Rozzano, Italy

16 Hospital Universitario Puerta de Hierro, Majadahonda, Spain

17 Hospital Universitario Miguel Servet, Zaragoza, Spain

18 The North Danish Regional Hospital, Hjørring, Denmark

19 Clínica Universidad de Navarra, Pamplona, Spain

20 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain|||Hospital de Mataró, Mataró, Spain

21 Hospital Universitario de Cabueñes, Gijón, Spain

22 Hospital Universitario Severo Ochoa, Leganés, Spain

23 Hospital Universitario Ramón y Cajal, Madrid, Spain

24 Hospital del Mar, Barcelona, Spain

25 Hospital General de la Defensa, Zaragoza, Spain

26 University Hospital Umberto I - Sapienza University of Rome, Roma, Italy

27 Hospital Santa Bárbara, Soria, Spain

28 Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

29 Hospital Universitario Santa María, Lérida, Spain

30 Hospital de Granollers, Granollers, Spain

31 Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Spain

32 Centre Hospitalier d’Antibes Juan-les-Pins, Antibes, France

33 Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Spain

34 Hospital Universitario de Donostia-Instituto Biodonostia, San Sebastián, Spain

35 Hospital Universitario Costa del Sol, Marbella, Spain

36 Hospital Sant Joan Despí Moisès Broggi, Sant Joan Despí, Spain

37 Hospital Universitario Central de Asturias, Oviedo, Spain

Event

UEG Week Berlin 2025

Topics

Histopathology Mechanisms & Personalised Medicine Oesophagus

Submission format

Abstract

Session

EoE: From gene to clinic

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

... for medical therapy in inflammatory bowel diseases

Chris Lamb 1

1 Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom

Event

UEG Week Berlin 2025

Topics

Colorectal IBD Surgery

Session

Predicting patient outcomes...

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Most popular content

Rate for better recommendations!